Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: A study in rhesus monkeys

Lancet

Volumn 362, Issue 9400, 2003, Pages 1953-1958

  Geisbert, Thomas W ^a   Hensley, Lisa E ^a   Jahrling, Peter B ^a   Larsen, Tom ^a   Geisbert, Joan B ^a   Paragas, Jason ^a   Young, Howard A ^b   Fredeking, Terry M ^c   Rote, William E ^d   Vlasuk, George P ^d  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Antibody Systems   (United States)

^d Dendreon   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT PROTEIN; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 7A INHIBITOR; D DIMER; FIBRIN; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; RECOMBINANT NEMATODE ANTICOAGULANT PROTEIN C2; RECOMBINANT PROTEIN; THROMBOPLASTIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; DATA ANALYSIS; DISEASE COURSE; DISEASE MODEL; DOSE RESPONSE; DRUG MEGADOSE; EBOLA VIRUS; EXPERIMENTAL INFECTION; EXPERIMENTAL MODEL; FEMALE; FIBRIN DEPOSITION; HEMORRHAGIC FEVER; INFLAMMATION; INJECTION; MALE; MORTALITY; NEMATODE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHESUS MONKEY; SURVIVAL RATE; THROMBOEMBOLISM; VIRUS INFECTION;

EID: 10744222633     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)15012-X     Document Type: Article

References (20)

1. Sanchez A., Khan A.S., Zaki S.R., et al. Filoviridae: Marburg and Ebola viruses. Knipe D.M., Howley P.M. Fields virology. 2001;1279-1304 Lippincott Williams and Wilkins, Philadelphia.
2. Geisbert T.W., Pushko P., Anderson K., Smith J., Davis K.J., Jahrling P.B. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis. 8:2002;503-507.
3. Jahrling P.B., Geisbert T.W., Geisbert J.B., et al. Evaluation of immune globulin and recombinant interferon α-2b for treatment of experimental Ebola virus infections. J Infect Dis. 179 (suppl 1):1999;S224-S234.
4. Huggins J., Zhang Z.X., Bray M. Antiviral drug therapy of filovirus infections: S-adenosylhomocysteine hydrolase inhibitors inhibit Ebola virus in vitro and in a lethal mouse model. J Infect Dis. 179 (suppl 1):1999;S240-S247.
5. Bray M., Driscoll J., Huggins J.W. Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor. Antiviral Res. 45:2000;135-147.
6. Huggins J.W., Zhang Z.X., Davis K., Coulombe R.A. Inhibition of Ebola virus by S-adenosylhomocysteine hydrolase inhibitors. Antiviral Res. 26:1995;A301.
7. Bray M., Hatfill S., Hensley L.E., Huggins J.W. Haematological, biochemical and coagulation changes in mice, guinea-pigs and monkeys infected with a mouse-adapted variant of Ebola Zaire virus. J Comp Pathol. 125:2001;243-253.
8. Geisbert T.W., Young H.A., Jahrling P.B., Davis K.J., Kagan E., Hensley L.E. Mechanisms underlying coagulation abnormalities in Ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis. 188:2003;1618-1629.
9. McVey J.H. Tissue factor pathway. Baillieres Best Pract Res Clin Haematol. 12:1999;361-372.
10. Arai A., Hirano H., Ueta Y., Hamada T., Mita T., Shirahata A. Detection of mononuclear cells as the source of the increased tissue factor mRNA in the liver from lipopolysaccharide-treated rats. Thromb Res. 97:2000;153-162.
11. Vlasuk G.P., Rote W.E. Inhibition of factor VIIa/tissue factor with nematode anticoagulant protein c2: from unique mechanism to a promising new clinical anticoagulant. Trends Cardiovasc Med. 12:2002;325-331.
12. Lee A., Agnelli G., Buller H., et al. Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation. 104:2001;74-78.
13. Moons A.H., Peters R.J., Bijsterveld N.R., et al. Recombinant nematode anticoagulant protein c2, an inhibitor of the tissue factor/factor VIIa complex, in patients undergoing elective coronary angioplasty. J Am Coll Cardiol. 41:2003;2147-2153.
14. Bick R.L. Disseminated intravascular coagulation: pathophysiological mechanisms and manifestations. Semin Thromb Hemost. 24:1998;3-18.
15. Iversen N., Strekerud F.G., Abildgaard U. Tissue factor pathway inhibitor (TFPI) in disseminated intravascular coagulation: low levels of the activated factor X-TFPI complex. Blood Coagul Fibrinolysis. 11:2000;591-598.
16. Funahara Y., Sumarmo, Wirawan R. Features of DIC in dengue hemorrhagic fever. Bibl Haematol. 49:1983;201-211.
17. Robson S.C., Shephard E.G., Kirsch R.E. Fibrin degradation product D-dimer induces the synthesis and release of biologically active IL-1 beta, IL-6 and plasminogen activator inhibitors from monocytes in vitro. Br J Haematol. 86:1994;322-326.
18. Johnson K., Choi Y., DeGroot E., Samuels I., Creasey A., Aarden L. Potential mechanisms for a proinflammatory vascular cytokine response to coagulation activation. J Immunol. 160:1998;5130-5135.
19. de Jonge E., Friederich P.W., Vlasuk G.P., et al. Activation of coagulation by administration of recombinant factor VIIa elicits interleukin 6 (IL-6) and IL-8 release in healthy human subjects. Clin Diag Lab Immunol. 10:2003;495-497.
20. de Pont A-C, Moons A.H., de Jonge E., et al. Recombinant nematode anticoagulant protein c2 (rNAPc2), an inhibitor of tissue factor/factor VIIa, attenuates coagulation and the IL-10 response in human endotoxemia. Blood. 100:2002;487a.